Abstract
Introduction Conclusions Background: Adenovirus (AdV) infection is accompanied by significant morbidity and mortality in high-risk pediatric patients. Treatment options are considerably limited by toxicity. Nephrotoxicity has been associated with cidofovir therapy, although most pediatric studies report little or no morbidity with its use. Pharmacokinetic (PK) data for children is limited; a pediatric PK study determined that cidofovir half-life was significantly longer in children than adults (Brown, 2015).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
